Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Cigall Kadoch

Foghorn Therapeutics Inc.

Sibylla Biotech is a preclinical stage company focused on developing small molecule degraders to find new therapeutics for unmet medical needs. The technology is powered by computer simulations and AI methods and is applicable to various therapeutic areas.

Sibylla Biotech

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Flagship Pioneering

Casdin Capital

Invus

Irving Investors

Happy New Year from all of us at Foghorn! As we kick off 2024, we look forward to the year ahead as we continue to advance our mission to transform patient’s lives by correcting abnormal gene expression. #biotechnology #innovation #oncology

Check out photos of our Foghorn team, who had fun swapping surprises at our end of year holiday party. From all of us at Foghorn, wishing everyone a healthy and happy holiday season! #HappyHolidays

That's a wrap on the 65th Annual American Society of Hematology Meeting! Our team enjoyed coming together with the scientific community to present data and talk about our novel approach to modulating the chromatin regulatory system. Read all of our recent data presentations from #ASH23 and beyond: https://bit.ly/3GJ2vkZ

Martin (Murphy) Hentemann Kathleen Healy Caroline Almon #biotechnology #innovation #TPD

Meet Alexia Kalogeropulou, one of our brilliant scientists at Foghorn. Alexia shares why she loves the collaborative culture that enables us to advance our mission to transform the lives of people living with a wide spectrum of diseases. #LifeAtFoghorn #WomenInSTEM #biotechnology

Join us at the 2nd Annual TPD Assay Development & Screening Summit, where our Head of #DrugDiscovery, Marina Nelen, will be part of a panel to discuss high-throughput screening approaches and applications of assay techniques to degrader triage and profiling. See the agenda: https://ow.ly/J9Bh50QfwVc
#biotechnology #innovation #proteindegradation

We’re looking forward to the 65th American Society of Hematology Annual Meeting and Exposition, where clinical data from the Phase 1 dose-escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented. Learn more: https://ow.ly/wc3q50Qel4h
#ASH23

We know that our people are the key to our success, which is why we embrace a people first culture. Our culture is just one reason that Madeleine Henley was drawn to Foghorn. Learn more about our culture: https://ow.ly/Ca4050Qe2u8 

#LifeAtFoghorn #WomenInSTEM

Happy #Thanksgiving to all! Today, we are especially thankful for the incredible Foghorn team and their unwavering commitment to our mission of transforming lives across a wide spectrum of diseases. #biotechnology #innovation

Last week, we had the pleasure of joining other leading experts in the chromatin and epigenetics field during #Epi2023, where Dave Lahr gave a presentation on our preclinical work during a session on the nucleosome and chromatin remodeling. Find all our recent data presentations here: https://lnkd.in/gUtu9Wfi

#biotechnology #oncology #innovation

Congratulations to this year's recipients of the 2023 Paul Marks Prize for Cancer Research, including our scientific co-founder, Cigall Kadoch! This award underscores the important work being done at Foghorn to address breakdowns in the chromatin regulatory targets to advance novel treatments in cancer and beyond. #oncology #cancerresearch #innovation

Metric
Company Name	Foghorn Therapeutics Inc.	Sibylla Biotech
Symbol	FHTX
MSH ID	COM:FOGHORNTX	IT:SIBYLLABIOTECH
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	IT
Stage
Employee Count	116
Website	foghorntx.com	sibyllabiotech.it
LinkedIn	foghorn-therapeutics
Founders

Metric
Market Cap	265.58M
Enterprise Value
Monthly Web Traffic	2.77K	18
Web Traffic Growth	-0.16	-0.99
Valuation
Raised Capital	110M

Metric
Revenue	34.16M
Revenue (LTM)
Revenue (NTM)
Gross Profit	25.49M
EBITDA	-99.25M
Operating Income	-107.91M
Net Income	-98.43M
EPS	-2.34
Diluted EPS	-2.34
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.93
Operating Profit Margin	-2.70
EBITDA Margin	-2.91
Net Profit Margin	-2.46
Return on Equity	1.89
Return on Assets	-0.26
Return on Capital Employed	-0.34

COM:FOGHORNTX

Foghorn Therapeutics Inc.

Last Close

7.72

22/11 21:00

Market Cap

265.58M

Beta: -

Volume Today

100.07K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.07
P/B Ratio	-2.02
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	15.72
EV Multiple	-2.58

Metric
Days Sales Outstanding
Days Payables Outstanding	123.31K
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-384.60
Asset Turnover	0.13

Metric
Operating Cash Flow	-118.11M
Free Cash Flow	-119.33M
Cash Flow to Debt	-2.62
Operating Cash Flow/Sales	-3.12
Free Cash Flow Yield	-1.04

Metric
Cash & Equivalents	80.34M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	1.54
Debt to Assets	0.15
Current Ratio	5.10
Quick Ratio	5.69

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.52
R&D to Revenue	3.49
SG&A to Revenue	1.02